Last reviewed · How we verify

PF-07836396 Influenza saRNA (pf-07836396-influenza-sarna)

Pfizer · FDA-approved active Quality 35/100

PF-07836396 Influenza saRNA (generic name: pf-07836396-influenza-sarna) is a Not specified drug developed by Pfizer. It is currently FDA-approved for Influenza.

PF-07836396 Influenza saRNA is a marketed drug by Pfizer Inc. for Influenza. It has a revenue of $63.6B. The mechanism of action is not specified. It has one clinical trial and no publications. This drug is a first-in-class treatment for Influenza.

At a glance

Generic namepf-07836396-influenza-sarna
SponsorPfizer
Drug classNot specified
TargetNot specified
Therapeutic areaInfectious Disease
PhaseFDA-approved

Approved indications

Common side effects

No common side effects on file.

Drug interactions

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about PF-07836396 Influenza saRNA

What is PF-07836396 Influenza saRNA?

PF-07836396 Influenza saRNA (pf-07836396-influenza-sarna) is a Not specified drug developed by Pfizer, indicated for Influenza.

What is PF-07836396 Influenza saRNA used for?

PF-07836396 Influenza saRNA is indicated for Influenza.

Who makes PF-07836396 Influenza saRNA?

PF-07836396 Influenza saRNA is developed and marketed by Pfizer (see full Pfizer pipeline at /company/pfizer).

What is the generic name of PF-07836396 Influenza saRNA?

pf-07836396-influenza-sarna is the generic (nonproprietary) name of PF-07836396 Influenza saRNA.

What drug class is PF-07836396 Influenza saRNA in?

PF-07836396 Influenza saRNA belongs to the Not specified class. See all Not specified drugs at /class/not-specified.

What development phase is PF-07836396 Influenza saRNA in?

PF-07836396 Influenza saRNA is FDA-approved (marketed).

What does PF-07836396 Influenza saRNA target?

PF-07836396 Influenza saRNA targets Not specified and is a Not specified.

Related